

## PRESS RELEASE

### **Multidisciplinary expert panel develops the first guidance on management of pancreatic cancer in Hong Kong**

(Hong Kong, 9 April 2024) – **The incidence of pancreatic cancer has been increasing in Hong Kong over the past two decades. The diagnosis and treatment of pancreatic cancer has been challenging due to its inconspicuous symptoms and aggressive clinical course, which results in patients frequently present with late-stage disease with relatively low cure rate. To improve the outcomes of pancreatic cancer, early recognition, accurate diagnosis and multidisciplinary treatment are essential. In light of this, an expert panel has developed the first guidance on management of pancreatic cancer in Hong Kong. The guidance has been published in the *Hong Kong Medical Journal*.**

In 2021, over 1100 people developed pancreatic cancer in Hong Kong.<sup>1</sup> There is a need for guidance on the management of pancreatic cancer in Hong Kong. Three academic clinicians from The Chinese University of Hong Kong and The University of Hong Kong have initiated a project to develop a set of consensus recommendations on the management of pancreatic cancer. A total of 12 local experts from different specialties including surgery, medicine, oncology, pathology and radiology participated in the project. By reviewing the literatures and discussing the relevance to Hong Kong, the group came up with 39 consensus statements covering the area of diagnosis, surveillance, treatment of different stages or severities of pancreatic cancer, approach on the personalised treatment, and palliative care of pancreatic cancer. Endorsed by the Hong Kong Society of Hepatobiliary and Pancreatic Surgery and the Hong Kong Cancer Therapy Society, the consensus recommendations provide references to clinicians in Hong Kong on diagnosis and treatment of pancreatic cancer.

The article “Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma” was published in the *Hong Kong Medical Journal*.  
<https://doi.org/10.12809/hkmj2210476>

## 新聞稿

### 多學科專家小組制定香港首份胰臟癌治療指南

(香港, 2024年4月9日) — 過去 20 年, 香港胰臟癌的發生率不斷上升。由於症狀不明顯和具侵襲性, 胰臟癌的診斷和治療一直具有挑戰性, 因此患者經常在晚期才確診, 治癒率亦相對較低。為了改善胰臟癌的治療效果, 早期識別、準確診斷和多學科治療至關重要。有見及此, 有專家小組制定了香港首份胰臟癌治療指南。有關指南已在《香港醫學雜誌》發表。

在 2021 年, 超過 1100 人罹患胰臟癌。<sup>1</sup> 香港需要有關胰臟癌治療的指引。來自香港中文大學和香港大學的三名臨床教授發起有關制定胰腺癌治療一系列共識建議的項目。共有 12 名來自外科、內科、腫瘤科、病理科及放射科等不同專業的本地醫生組成專家小組, 透過回顧文獻以及商討有關文獻數據在香港的應用, 最終制定了 39 項共識聲明, 內容涵蓋胰臟癌不同階段或嚴重程度的診斷、監測、治療、個人化治療和舒緩治療的方法。該份共識建議已獲香港肝膽胰外科學會及香港腫瘤化療學會認可, 為本港臨床醫生在胰臟癌的診斷和治療方面提供參考。

詳細內容可參閱原文《香港有關胰腺導管腺癌治療的共識聲明》。

#### Reference

1. Hospital Authority. Overview of Hong Kong Cancer Statistics of 2021. October 2023. Available from: <https://www3.ha.org.hk/cancereg/pdf/overview/Overview%20of%20HK%20Cancer%20Stat%202021.pdf>. Accessed 19 Mar 2024.

###

Source: SL Chan, CL Chiang, Kenneth SH Chok, et al. Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma. Hong Kong Med J 2024;30:Epub 9 Apr 2024. <https://doi.org/10.12809/hkmj2210476>.

Follow us:  